Recently, two randomized, open-label, phase 3 trial showed that platinum-etoposide plus programmed cell death-Ligand 1(PD-L1) inhibitor followed by maintenance PD-L1 inhibitor achieved OS benefits vs. chemotherapy in advance stage SCLC. Here, CD274 is linked to small cell lung carcinoma.